KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2025)

Historic Raw Materials for Rigel Pharmaceuticals (RIGL) over the last 5 years, with Q3 2025 value amounting to $7.0 million.

  • Rigel Pharmaceuticals' Raw Materials rose 34295.73% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 34295.73%. This contributed to the annual value of $1.1 million for FY2024, which is 7663.27% down from last year.
  • Rigel Pharmaceuticals' Raw Materials amounted to $7.0 million in Q3 2025, which was up 34295.73% from $9.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Raw Materials high stood at $9.6 million for Q2 2025, and its period low was $1.1 million during Q4 2024.
  • Moreover, its 5-year median value for Raw Materials was $4.6 million (2022), whereas its average is $4.6 million.
  • Its Raw Materials has fluctuated over the past 5 years, first crashed by 7663.27% in 2024, then skyrocketed by 34876.46% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Raw Materials stood at $5.1 million in 2021, then decreased by 11.42% to $4.6 million in 2022, then rose by 1.19% to $4.6 million in 2023, then tumbled by 76.63% to $1.1 million in 2024, then soared by 545.31% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $9.6 million for Q2 2025, and $1.1 million during Q1 2025.